mismatch repair deficiency Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 13, 2022 MSK Researchers Testing if Chemo-Induced Hypermutated Colon Cancers Respond to BMS' Opdivo Mar 25, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Mar 17, 2022 NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers Aug 18, 2021 FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers Jun 29, 2021 BMS' Opdivo, Yervoy Combo Approved for dMMR, MSI-High Colorectal Cancer in Europe Jun 14, 2021 UK's NICE Recommends Approval of Opdivo, Yervoy for MSI-High, MMR-Deficient Colorectal Cancer May 24, 2021 EMA's CHMP Recommends Approval for BMS' Opdivo Plus Yervoy for Certain Colorectal Cancer Patients May 14, 2021 NICE Recommends Keytruda for Metastatic MSI-High, Mismatch Repair-Deficient Colorectal Cancer Apr 23, 2021 European Commission Approves GSK's Dostarlimab in Endometrial Cancer Apr 22, 2021 FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer Mar 25, 2021 Oncologists Look to FDA as New Publications Poke Holes in TMB-High Keytruda Approval Premium Mar 19, 2021 In Brief This Week: Merck, Clovis Oncology, Grail, GenomOncology, Veracyte, Amoy Diagnostics Feb 26, 2021 CHMP Recommends Approval of GSK's Dostarlimab in Endometrial Cancer Jan 26, 2021 Merck Nabs EU Keytruda Approval for MSI-High, Mismatch Repair Deficient Colorectal Cancer Dec 16, 2020 Merck, Eisai to Discuss Positive Keytruda, Lenvima Data in Endometrial Cancer With Regulators Dec 11, 2020 EMA Committee Recommends Approval of Keytruda in MSI-H Colorectal Cancer Jun 29, 2020 FDA Approves Merck's Keytruda as First-Line Treatment for MSI-H Metastatic Colorectal Cancer Apr 24, 2020 New Data Show Response for Subset of Endometrial Cancer Patients Treated With GSK's Dostarlimab Load More Breaking News Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody
